Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which shot works best for stubborn back pain? new study aims to find out

NCT ID NCT07632820

First seen Jun 08, 2026 · Last updated Jun 20, 2026 · Updated 4 times

Summary

This study compares two common injection treatments for chronic mid-back pain: the erector spinae plane (ESP) block and trigger point injections (TPI). About 76 adults with pain lasting at least three months will be randomly assigned to receive one of the two injections. Researchers will track pain levels, physical function, and well-being for up to 12 weeks to see which treatment provides better relief.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACK PAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Ohio State University Wexner Medical Center

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Maryland

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Bupivacaine (a local anesthetic)

What this could lead to

If this trial shows one injection works better, it could give doctors a clearer choice for treating stubborn mid-back pain.

What could go wrong

This is a small, early-phase study with only 76 people. The results may not apply to everyone, and pain relief from injections can be temporary.

Conditions

The condition(s) this trial relates to.

Back Pain myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.